chevron_leftBack
As of 24 April 2025, Annovis Bio, Inc. has a market cap of $29.42M USD, ranking #27732 globally and #4178 in the United States. It ranks #2791 in the Healthcare sector, and #919 in the Biotechnology industry.
Key Stats
Market Cap
$29.42MUSD
Enterprise Value
$18.87MUSD
Net Income (TTM)
-$24.59MUSD
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Maria Maccecchini
open_in_new
Employees
15
Founded
2008
IPO
29 Jan 2020
Website
annovisbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 2.7% | 19% | -14% | -72% | -84% | -87% |
Upcoming Earnings
Earnings Date
Mon, May 12
Earnings Time
sunny
Before Open
EPS Estimate
-$0.2900
Revenue Estimate
-
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ANVS
Annovis Bio Inc Ordinary Shares
ISIN: US03615A1088
Shares Out.:
Shares Outstanding:
19.486M1
Shares Float:
16.671M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.51 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer’s disease, as well as in phase 3 to treat parkinson’s disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer’s disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
